Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis

Y. YOSHIGA¹, D. GOTO¹, S. SEGAWA¹, Y. OHNISHI², I. MATSUMOTO¹, S. ITO¹, A. TSUTSUMI¹, M. TANIGUCHI¹ and T. SUMIDA¹

¹Division of Clinical Immunology, Major of Advanced Biomedical Applications, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba; ²Mitsubishi Chemical Safety Institute Ltd, Ibaraki; ³Riken Research Center for Allergy and Immunology, Yokohama, Japan

Received March 11, 2008; Accepted April 29, 2008

DOI: 10.3892/ijmm_00000032

Abstract. Invariant natural killer T (iNKT) cells play a protective role in the development of certain autoimmune diseases. However, their precise role in the pathogenesis of autoimmune arthritis remains unclear. In this study, we examined the possible contribution of iNKT cells in collagen-induced arthritis (CIA) by using iNKT cell-deficient mice (Jo281-/- mice). CIA in these mice was markedly suppressed and interleukin (IL)-17 production was reduced in a native type II collagen (CII)-specific T cell response. Draining lymph nodes of CII-immunized Jo281-/- mice contained a significantly low number of IL-17-producing T helper cells. To determine whether iNKT cells produce IL-17, we measured IL-17 by enzyme-linked immunosorbent assay in iNKT cells stimulated with the ligand, α-galactosylceramide (α-GalCer). Notably, splenocytes from Jo281-/- mice stimulated in this way were negative for IL-17, whereas those from C57BL/6 mice produced IL-17. Immunostaining for IL-17 in iNKT cells confirmed intracellular staining of the protein. RT-PCR analysis showed that iNKT cells expressed retinoid-related orphan receptor γT and IL-23 receptor. Moreover, cell sorting demonstrated that NK1.1- iNKT cells were the main producers of IL-17 compared with NK1.1+ iNKT cells. IL-17 production by iNKT cells was induced by IL-23-dependent and -independent pathways, since iNKT produced IL-17 when stimulated with either IL-23 or α-GalCer alone. Our findings indicate that iNKT cells are producers and activators of IL-17 via IL-23-dependent and -independent pathways, suggesting that they are key cells in the pathogenesis of CIA through IL-17.

Introduction

Natural killer T (NKT) cells are a subset of T lymphocytes that express NK-cell markers, such as NK1.1 in mice. The majority of NKT cells express an invariant T cell receptor (TCR) encoded by Vα14-Jα281 associated with highly skewed sets of Vßs, mainly Vß8.2 in mice, and they are therefore called invariant NKT (iNKT) cells. The receptor recognizes glycolipid antigen presented by CD1d, a nonclassical antigen-presenting molecule (1,2). TCR stimulation induces iNKT cells to rapidly secrete large amounts of pro- and anti-inflammatory cytokines, such as interleukin (IL)-4 and interferon (IFN)-γ (3). iNKT cells are therefore known as immune regulators.

Deficiency of iNKT cells is associated with various autoimmune diseases (4-7). In animal models, iNKT cells suppress the development and progression of diabetes mellitus (8), experimental autoimmune encephalitis (EAE) (9), and systemic lupus erythematosus (10). These cells also act as effector cells in autoimmune arthritis by promoting T helper (Th) 1-type immune responses, inducing the production of autoantibodies, and suppressing the production of transforming growth factor (TGF)-β (11-14). The evidence thus suggests a dual function for iNKT cells in autoimmunity.

Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation of the synovial tissues in multiple joints leading to joint destruction (15). Although the etiopathogenesis of RA remains unclear, pro-inflammatory cytokines including tumor necrosis factor (TNF)-α, IL-1β, and IL-6 play a major role in this process (16). It is generally accepted that IFN-γ-producing Th1 cells play a pathogenic role in the development of autoimmune diseases. In addition, IL-17 from CD4+ effector T cells, but not IFN-γ, was recently implicated in the pathogenesis of EAE and collagen-induced arthritis (CIA) (17,18).

IL-17 is a T cell-derived cytokine associated with a variety of autoimmune diseases. The trigger for IL-17 release
has not been fully elucidated, but IL-23 is known to promote the production of IL-17 (19). Specifically, differentiated Th17 cells express IL-23 receptor (IL-23R) as well as orphan nuclear receptor retinoid-related orphan receptor (ROR) γT (20,21). Furthermore, IL-23-dependent IL-17-producing CD4+ effector T cells, which develop via a lineage distinct from Th1 and Th2 cells, play a pathogenic role in EAE and CIA (17,18,22). IL-17 is a potent inducer of various cytokines from Th1 and Th2 cells, play a pathogenic role in EAE and CIA (17,18,22). IL-17 is a potent inducer of various cytokines such as TNF-α, IL-1, and receptor activator of NF-κB ligand (RANKL), and is involved in synovial inflammation, cartilage destruction, and bone erosion (23). Moreover, IL-17-deficient or -deficient mice are resistant to the development of CIA (24-26).

The present study was designed to assess the role of iNKT cells in the development of one form of autoimmune arthritis, CIA, by using iNKtet-deficient mice (Jo281α-/- mice). The results demonstrated that production of IL-17 was significantly reduced in iNKtet deficient mice. The results also showed that iNKT cells produce IL-17 in IL-23-dependent and -independent pathways. The majority of IL-17-producing iNKT cells were of the NK1.1+ population. The findings implicating iNKT cells as producers and activators of IL-17, making them key players in the pathogenesis of CIA via IL-17.

Materials and methods

Mice. C57BL/6 (B6) mice were purchased from Charles River Japan Inc. (Tokyo, Japan). Jo281α-knockout mice were kindly provided by Dr Masaru Taniguchi (Riken Research Center for Allergy and Immunology, Yokohama, Japan). The animals were kept under specific pathogen-free conditions and studied at 6–9 weeks of age. The Committee on Institutional Animal Care and Use at Tsukuba University approved all experimental plans.

Induction of CIA. Mice were immunized intradermally at the base of their tails with 100 μg of chicken CII emulsified with an equal volume of complete Freund’s adjuvant (CFA) and containing 250 μg of H37Ra Mycobacterium tuberculosis (Difco, Detroit, MI). The animals were boosted by intradermal injection with the same antigen preparation on day 21. Joint swelling was monitored and scored as follows: 0, no swelling or redness; 1, swelling or redness in one joint; 2; two or more joints involved; 3; severe arthritis of the entire paw and joint. The score for each animal was the sum of the score for all joints involved, 3; severe arthritis of the entire paw and joint. Flank swelling was monitored and scored as follows: 0, no swelling; 1, swelling; 2, two or more paws involved; 3, severe arthritis of the entire paw and joint.

Flow analysis and sorting of iNKT cells. Prior to antibody staining, cells were preincubated with anti-CD16/32 to block nonspecific FeR binding. The following antibodies were used in this study: FITC-conjugated anti-CD19 (BD Pharmingen, San Diego, CA), FITC-conjugated anti-CD4 (BD Pharmingen), FITC-conjugated anti-NK1.1 (eBioscience, San Diego, CA), PE- or APC-conjugated CD1d tetramer (PE, Medical & Biological Laboratories Co., Nagoya, Japan; APC, Proimmune), and Per-CP-conjugated anti-CD3 (BD Pharmingen). Samples were acquired on a FACScalibur instrument (Pharmingen) and data were analyzed with FlowJo software.

Intracellular cytokine staining. Standard intracellular cytokine staining was performed as described previously (BD Bioscience, San Jose, CA). Cells were first stained for a cell surface marker, then fixed and permeabilized with Cytofix/Cytoperm solution (Pharmingen), before further immunostaining with PE-conjugated anti-IL-17 (Pharmingen) or FITC-conjugated anti-IFN-γ (eBioscience), FITC-conjugated anti-IL-4 (eBioscience), PE-conjugated Isotype Rat IgG (Pharmingen), and FITC-conjugated Isotype Rat IgE (eBioscience).

Measurement of ex vivo CIA-specific T cell response. B6 and Jo281α-/- mice were immunized intradermally with 100 μg chicken CII emulsified in CFA containing 250 μg of inactivated M. tuberculosis H37Ra. At 10 days after CII/CFA immunization, draining lymph node (DLN) cells were restimulated in triplicate with 100 μg/ml chicken CII for 72 h. IL-17 concentrations in the culture supernatant were measured by enzyme-linked immunosorbent assay (ELISA). Analysis of cytokine production by DLN cells was performed by first isolating these cells from B6 and Jo281α-/- mice at 10 days after CIA immunization, and then their culture (1x10^6 cells/ml) for 72 h in 96-well plates with 100 μg/ml of CII. Golgistop (BD Pharmingen) was added for the final 6 h of culture before cytokine staining to enhance intracellular protein accumulation.

Activation of iNKT cells in vitro. Splenocytes from B6 and Jo281α-/- mice were collected and stimulated with or without 100 ng/ml or sequential amounts (0, 1, 10, 100, 1000 ng/ml) of α-galactosylceramide (α-GalCer), for 72 h in 96-well round-bottom plates. Cytokine concentrations in the culture supernatants were measured by ELISA. The cells were cultured for intracellular cytokine staining. In experiments shown in Fig. 4, sorted total iNKT cells, NK1.1+ iNKT cells or NK1.1- iNKT cells (2x10^4 cells/well) were cultured with mitomycin-C-treated CD11c+ cells (2x10^4 cells/well), which were selected by MACS CD11c-beads from splenocytes as antigen-producing cells (APC), in the presence or absence of 10 ng/ml IL-23 (eBioscience) and/or 10 μg/ml α-GalCer (Kirin Brewery Co.). For neutralization of IL-23, splenocytes were stimulated with 10 ng/ml α-GalCer or 100 μg/ml rIL-23 (eBioscience) plus 100 IU/ml IL-2 for 72 h in the presence of sequential amounts of anti-IL-23 antibody (0, 0.3, 1, 3 μg/ml; eBioscience) or isotype-matched control IgG (eBiosciences).

RT-PCR. Total RNA was extracted from purified iNKT cells, B cells and Th17 cells, and was reverse transcribed into cDNA using RevertAid™ First-strand cDNA Synthesis kit (Fermentas, Burlington, ONT, Canada) according to the protocol supplied by the manufacturer. iNKT cells (CD1d tetramer+CD3+CD19- cells) were sorted from naive or α-GalCer-stimulated splenocytes. B cells were purified from α-GalCer-stimulated splenocytes using anti-CD19 magnetic microbeads as recommended by the manufacturer (Miltenyi Biotec, Bergisch Gladbach, Germany). For induction of Th17 cells, MACS-purified CD4+ T cells were cultured with 20 ng/ml IL-6 (eBioscience) and 5 ng/ml TGF-β (R&D Systems, Minneapolis, MN) in 96-well plates containing plate bound anti-CD3 (5 μg/ml) and soluble anti-CD28 (1 μg/ml)
for 3 days. The following primers were used for PCR: GAPDH: forward AACTTTGGCATTGTGGAAGG, reverse ACACATTGGGGGTAGGAACA; IL-17: forward TCCAGAAGGCCCTCAGACTA, reverse AGCATCTTCTCGACCCTGAA; and RORγT: forward TGCAAGACTCATGACAGACAAGG, reverse AGGGGATTCAACATCAGTGC. The results were normalized with GAPDH expression.

Statistical analysis. The Mann-Whitney U Test was used for comparisons of clinical score of arthritis and ex vivo T cell response. The Student's t-test was used for in vitro iNKT cell response. P<0.05 denoted the presence of a statistically significant difference.

Results

iNKT cells promote joint inflammation. iNKT cells act as regulatory cells in some autoimmune diseases. However, in the development of autoimmune arthritis, an effector function has been assigned to these cells (11-14). To confirm the specific role of iNKT cells in the development of collagen-induced arthritis (CIA), we examined the incidence and severity of arthritis in iNKT cell-deficient Jα281−/− mice and B6 controls. The incidence of arthritis and disease severity in mice lacking iNKT cells was markedly lower than in B6 mice (Fig. 1A and B). These results suggest that iNKT cells promote joint inflammation in the development of CIA.

iNKT cells enhance IL-17 production. We examined whether the presence or absence of iNKT cells altered the T cell response to type II collagen (CII). We isolated the draining lymph node (DLN) cells from B6 mice and iNKT cell-deficient mice 10 days after the first immunization with CII, and then further stimulated the DLN cells with CII in vitro. There was significantly less IL-17 in the culture supernatant of Jα281−/− mice than in cultures of B6 DLN cells. However, the concentrations of IL-4, IL-10, and IFN-γ did not differ between these mice (Fig. 2A). It was suggested that IL-17-producing CD4+ T cells (Th17 cells) play a crucial role in the generation of autoimmune diseases (17,18,20). To determine whether iNKT cells accelerate IL-17 production by Th17 cells in CIA, we measured cytokine production by CD4+ T cells in DLN. The percentage of IL-17-producing CD4+ T cells (Th17 cells) was lower in Jα281−/− mice than in B6 mice (Fig. 2B, P<0.01), suggesting that iNKT cells enhance Th17 cell activation in the development of CIA.

iNKT cells synthesize and secrete IL-17. We hypothesized that iNKT cells directly produced IL-17 and that IL-17 promoted the pathogenesis of CIA. We stimulated iNKT cells obtained from naive B6 and iNKT cell-deficient mice with the iNKT cell ligand, α-GalCer. Isolated splenocytes were further stimulated with α-GalCer, and the amount of IL-17 in the culture supernatant was assayed. iNKT cells from B6 mice stimulated with α-GalCer showed dose-dependent IL-17 production, while iNKT cell-deficient mice were negative for IL-17 (Fig. 3A and B). The α-GalCer-stimulated splenocytes were then immunostained to localize IL-17 and identify the IL-17-producing cells (Fig. 3C). Notably, a small population of IL-17+ iNKT cells was observed in B6 mice, but none were
evident in the Jα281-/- mice (Fig. 3C), suggesting that iNKT cells themselves produce IL-17. Moreover, IL-17-producing iNKT cells did not produce IFN-γ or IL-4 (Fig. 3D). The above experiments indicate the presence of IL-17-producing iNKT cells, although there is no evidence that IL-17-producing iNKT cells are specifically Th17 activators.

NK1.1 iNKT cell-mediated IL-17 production is dependent on and independent of IL-23. IL-23 is a heterodimeric protein consisting of common IL-12p40 and IL-23p19 and is essential for maintenance of Th17 cells (18,19). To establish whether the same effect was seen in iNKT cells, we analyzed the expression of IL-23R as well as RORγT by RT-PCR. As shown in Fig. 4A, naive and activated iNKT cells expressed IL-17, RORγT and IL-23R in a similar manner, indicating that iNKT cells are capable of producing IL-17 in response to IL-23.

Figure 3. Glycolipid antigen-stimulated iNKT cells synthesize and secrete IL-17. (A) Splenocytes from naive B6 and Jα281-/- mice were collected and stimulated with or without α-GalCer for 72 h in triplicate. IL-17 levels in the supernatant were measured by ELISA. (B) Splenocytes from B6 mice were stimulated with various concentrations of α-GalCer (0, 1, 10, 100, 1000 ng/ml) and IL-17 levels in the supernatants were then measured by ELISA. (C) Top panels: population of splenocytes from B6 or Jα281-/- mice stimulated with or without α-GalCer for 72 h. The CD19-CD4+ tetramer + CD3+ cells were counted as iNKT cells. Bottom panels: IL-17 production by splenocytes from B6 or Jα281-/- mice stimulated with or without α-GalCer for 72 h. CD19-CD3+ cells were gated and IL-17-CD4+ tetramer + cells were estimated as IL-17-producing iNKT cells. (D) Intracellular IL-17, IFN-γ and IL-4 staining was performed after in vitro stimulation of splenocytes at 72 h and analyzed among gated iNKT cells (CD1d tetramer+CD3+) by flow cytometry. Data are representative of three independent experiments.

Figure 4. Phenotype of IL-17-producing iNKT cells. (A) IL-17, RORγT and IL-23R expression in purified iNKT cells was determined by using RT-PCR. Lane 1, iNKT cells from naive splenocytes; Lane 2, iNKT cells from α-GalCer-stimulated splenocytes; Lane 3, Th17 cells; Lane 4, B cells from α-GalCer-stimulated splenocytes. (B) Representative FACS profiles of sorted total iNKT cells, NK1.1+iNKT cells and NK1.1-iNKT cells. The purity of iNKT cells in this experiment was >95% (total iNKT), >78% (NK1.1+iNKT) and >72% (NK1.1-iNKT). (C) Sorted total iNKT cells, NK1.1+iNKT cells, and NK1.1-iNKT cells were co-cultured with mitomycin-C-treated CD11c as APC and stimulated with IL-23, α-GalCer, or IL-23 plus α-GalCer. IL-17 was measured in the supernatants after 72 h. No IL-17 was detected in unstimulated total iNKT, NK1.1+iNKT, and NK1.1-iNKT cells. (D) Splenocytes were stimulated with α-GalCer or rIL-23 plus rIL-2 in the presence of anti-IL-23 mAb or control Ig. IL-17 was measured in the supernatants after 72 h. *P<0.01; **P<0.001. Data are representative of three independent experiments. N.S, not significant.
naive B6 mice were sorted into either NK1.1-iNKT cells, was dependent or independent of IL-23, splenocytes from
expression in joints, suggesting an effector-cell function
as IL-17 producers and activators in autoimmune arthritis.

Moreover, we propose two functional roles for iNKT cells in the development of CIA. The first is upregulation of IL-17 production by CII-reactive Th17 cells, while the second is direct production of IL-17 (Fig. 5).

IL-17 is a pathogenic cytokine in autoimmune diseases such as EAE and CIA, since its neutralization or deficiency reduces the severity of disease (24-26). Our study demonstrated that deficiency of iNKT cells reduced CII-reactive IL-17 production in CIA mice. These findings suggest that iNKT cells are associated with IL-17 production and that these cells play a crucial role in the development of CIA.

Previous studies showed that Th17 cells are distinct from the traditional Th1- and Th2-cell subsets, and that they are important in regulating tissue inflammation and the development of disease in several animal models of autoimmunity (20,22,28,29). TGF-β promotes Th17-cell development in the presence of IL-6 (30-32), and IL-23 is critical for the maintenance of Th17-cell activation in chronic inflammation (20). Our study demonstrated that iNKT cells enhance IL-17 production by Th17 cells in CIA. Some reports have shown that activated iNKT cells induce maturation of DC, and thereby, enhance the antigen-specific T cell response (33,34).

In addition, Eberl et al (35) suggested that iNKT cells contribute to the maintenance and persistent stimulation of memory T cells through cytokine secretion. Recent reports suggested that IL-21, which activates Th17 cells (36-38), is produced by iNKT cells (39,40). Thus, we speculate that iNKT cells might maintain or activate Th17 cells in CIA mice.

In this study, we clearly demonstrated that iNKT cells synthesize and release IL-17 in addition to accelerating IL-17 production by Th17 cells. Moreover, the main cell population of IL-17-producing iNKT cells is NK1.1+ cells. In recent study, Michel et al (27) reported a similar finding in relation to IL-17-producing iNKT cells. Although the function of NK1.1 in IL-17 production is not clear at present, NK1.1 may be a key regulatory molecule in IL-17 production by iNKT cells. In our study, we demonstrated that iNKT cells expressed RORγT as well as Th17 cells, indicating that RORγT might also be involved in IL-17 production by iNKT cells as well as Th17 cells.

Several IL-17-producing cells have been identified, such as CD4 T cells (Th17) and γδ T cells, with IL-17 production dependent on IL-23. In contrast, Mangan et al (32) detected IL-17 in IL-23-deficient mice and Liu et al (41) showed short-term production of IL-17 induced by TCR stimulation in the absence of IL-23. Thus, IL-17 might be regulated in an IL-23-dependent or -independent manner. In our system, iNKT cells produced IL-17 not only by IL-23 but also by α-GalCer alone. Therefore, IL-17 production by iNKT cells is regulated by two distinct pathways (Fig. 5).

In conclusion, we demonstrated that iNKT cells can produce IL-17 by themselves and enhance Th17 cell activity, thus playing a significant role in the development of collagen-induced arthritis (CIA). Moreover, we also showed that iNKT cells (mainly the NK1.1+ cell population) can secrete IL-17 through two stimulation pathways, the IL-23-IL-23R pathway and the glycolipid antigen-TCR pathway.

**Discussion**

iNKT cells act as regulatory cells in certain autoimmune diseases. However, in the development of autoimmune arthritis, an effector function has been assigned to these cells (11-14). Both the severity of arthritis and autoantibody production was reduced in iNKT cell-deficient mice with CIA (11,12). In addition, the T cell response to autoantigens shifted from Th1 to Th2 in these mice (11). Furthermore, in antibody-induced arthritis, iNKT cells suppressed TGF-β expression in joints, suggesting an effector-cell function (13,14). The present results indicate that iNKT cells function as IL-17 producers and activators in autoimmune arthritis. This is the first time that the role of iNKT cells through IL-17 production in the development of CIA has been reported.
Acknowledgements

We thank Dr F.G. Issa for a critical reading of the manuscript. This study was supported in part by the Japanese Ministry of Science and Culture, and the Japanese Ministry of Health, Labour and Welfare.

References


